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TECHNICAL NOTE
Balloon control of the saphenofemoral junction
during foam sclerotherapy: Proposed innovation
Anamay Bidwai, MBBS, Timothy Beresford, MBBS, Michael Dialynas, FRCS, John Prionidis, FRCS,
Yiannis Panayiotopoulos, MD, PhD, and Tom F. Browne, FRCS, Chelmsford Essex, United Kingdom
Venous obliteration using foam sclerosant is a relatively new procedure that holds great promise and may prove to be as
effective as conventional surgical treatments in obliteration of the great saphenous vein. Foam sclerotherapy can have
minor and major complications, most of which occur as a result of gas or sclerosant leakage into the systemic venous
system. Conventionally, the saphenofemoral junction is occluded by digital pressure to prevent escape of sclerosant foam
into the deep venous system. We propose balloon control of the saphenofemoral junction to prevent sclerosant leakage.
This also promotes foam contact with the endothelium in a prolonged, controlled fashion. This method requires no
anesthesia, is suitable for ambulatory care, and has been safe and successful in all five cases. Duplex examinations at 1 week
and 3 months have shown complete obliteration of the great saphenous vein using this technique. (J Vasc Surg 2007;46:
145-7.)Venous obliteration using sclerosant foam has become
topical again. It holds great promise and may prove to be as
effective as conventional surgical treatments.1,2 Sclerosant
foam therapy is a relatively simple procedure to perform
and is usually accomplished without anesthesia.1 The re-
cent changes to surgical treatment of varicose veins have
been accommodated by ready access to duplex-guided
imaging, new foaming techniques, endovenous laser abla-
tion, and radiofrequency obliteration.3
Foam sclerotherapy can have both minor and major
complications. Minor complications can include ocular mi-
graine, true migraine, chest tightness, visual disturbances,
paresthesias, and bruising.1,4 Reported major complication
are deep venous thrombosis (DVT), femoral vein throm-
bosis, and stroke.1,4,5 The United States Food and Drug
Administration halted a clinical phase 2 trial of a commer-
cial preparation of polidocanol microfoam in 2003 because
of concerns relating to possible gas embolism. These trials
were recommenced in July 2005. This report illustrates
strong circumstantial evidence confirming the potential for
embolic complication when this foam is used.5
The results of treatment are comparable with surgical
intervention, with a small percentage of patients presenting
complications, including DVT of the gastrocnemius and
posterior tibial veins.1 A case of femoral vein thrombosis
was reported in a large multicenter study of sclerotherapy.4
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leakage of foam from the saphenofemoral junction (SFJ) or
perforators.
Conventionally, the SFJ is occluded by digital pressure
to prevent the escape of sclerosant foam into the deep
venous system; however, this method does not reliably
prevent leakage through the perforators or the SFJ. We
propose a safety measure that is applied under ultrasound
guidance and can minimize complications associated with
foam sclerotherapy and help in the obliteration of the great
saphenous vein (GSV).
PATIENTS AND METHOD
Five patients, all aged older than 65 years, underwent
foam sclerotherapy in which local anaesthetic was used and
the proposed innovation was incorporated. All patients
underwent preoperative duplex imaging that showed iso-
lated incompetent GSVs and patent deep systems.
Preoperatively, patient’s veins were marked while they
were in an upright position by using a duplex machine.
Patients were then positioned supine on the operating
table. An ultrasound probe was covered in a polyethylene
sheath (civico). The limbs were prepared using antiseptic,
and the patients were draped.
Perforators were located by duplex imaging (Titan,
SonoSite, Bothell, Wash) and occluded by using a clip
applicator. To access the perforators, a small incision was
made under local anesthetic. The number of perforators
clipped (Lega clip 20/20, Ethicon, Somerville, NJ) ranged
from zero to four (Fig 1).
The GSV was accessed below the knee with an arterial
needle under duplex control. A V18 Control wire (Boston
Scientific, Natick, Mass) was introduced and followed to
the groin. A Brite Tip long introducer and sheath (Cordis/
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using the Seldinger technique (Fig 1). The technique of
using a long intravenous catheter has already been de-
scribed by Milleret and Garandeau.6 The position of the
wire tip at the SFJ was confirmed by ultrasound imaging.
The size of the vein at the junction was measured and a
corresponding over-the-wire Fogarty catheter (LeMaitre
Vascular, Burlington, Mass) was introduced coaxially.
Patients were then put in Trendelenburg position. The
balloon of the over-the-wire Fogarty catheter was inflated
2 cm short of the SFJ, resulting in complete occlusion of
the GSV (Fig 2).
Foam was prepared using 2 mL of sodium tetradecyl
sulphate (3%) with 10 mL of air in two separate 5-mL
syringes. The Tessari technique was used. The micro-
Fig 1. Drawing demonstrates the tip of V18 wire (Bos
(SFJ), the clipped perforators, long sheath, and introduc
Fogarty being threaded over the V18 wire.
Fig 2. Drawing demonstrates the inflated balloon of the over-
the-wire Fogarty catheter occluding the saphenofemoral junction.bubbles in the foam provide an enormously increased areaof surface contact.7 Foam was injected (range, 5 to 10 mL)
through the side arm of the long sheath. Injection of the
foam was continued as the sheath was withdrawn to expose
the distal end of the GSV to foam (Fig 3). The foam was left
in contact with the GSV for 5minutes. This was timed from
the time of injection to the time when the balloon was
deflated (Fig 4).
The V18 Control wire and long sheath were withdrawn
first, and a small plaster was applied to the entry site. A thin
line of sponge was placed along the line of the GSV, and
cientific, Natick, Mass) at the saphenofemoral junction
the great saphenous vein (GSV), and the over-the-wire
Fig 3. Drawing demonstrates the foam being injected (inset)
from the side channel of long sheath, the Fogarty balloon occlud-
ing the saphenofemoral junction (SFJ), and the sheath being
gradually withdrawn to expose the distal end of great saphenous
vein to foam.ton S
er incompression with a Panelast Acryl (Vernon-Carus Ltd,
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from foot to high thigh. The balloon was deflated after the
compression was in place, and the leg was returned to the
horizontal position.
The patients were then brought to the recovery room.
No analgesics were prescribed. On discharge, the patients
were encouraged to remain mobile and active. Compres-
sion dressings were left in place for 1 week and then
replaced by a thromboembolic deterrent stocking.
RESULTS
All the patients were discharged from the hospital
within 2 to 3 hours of the procedure. The compression
bandage was removed at 1 week and replaced by an antiem-
bolic stocking. The clinical examination at the 1-week visit
revealed minor signs and symptoms relative to the proce-
dure. No evidence of DVT was found on duplex examina-
tion. A duplex examination for all patients was repeated at 3
months, and the treated segments were completely obliter-
ated in all five patients. There were no complications of
either a major or minor nature.
DISCUSSION
Leak of sclerosant foam into the deep venous system
Fig 4. Drawing demonstrates the completed procedure but does
not show the compression. Collapsed balloon of the-over-the wire
Fogarty is being pulled out, and the sheath is almost out.from perforators and the SFJ junction has the potential toresult in major and minor complications. Digital pressure is
not reliable enough and results in leakage of sclerosant and
gas into the deep venous system. Our use of an over-the-
wire embolectomy catheter balloon eliminates the need for
digital compression, and brings about uniform and pro-
longed contact of the foam with the endothelium. The
completely blocked SFJ generates a static column of scle-
rosant foam, bringing about uniform contact with the
venous endothelium.
As mentioned in “Methods,” clipping the perforators
before instillation should reduce the chances of foam escap-
ing into the systemic venous circulation. Clipping of perfo-
rators also helps to further strengthen the static column of
foam in the treated segment of vein.
CONCLUSION
We propose that this innovation of blocking the SFJ
with an over-the-wire Fogarty balloon, along with clipping
of perforators, can almost completely prevent leakage of gas
and sclerosant into the deep venous system. This in turn,
should minimize complications and improve the chances
of success. The method is ideal for ambulatory care. This is
a safe, simple, and cost-effective procedure that is well
tolerated by patients.
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